

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **January 10, 2011**

Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-33137
(Commission
File Number)

14-1902018
(IRS Employer
Identification No.)

2273 Research Boulevard, Suite 400, Rockville, Maryland
(Address of Principal Executive Offices)

20850
(Zip Code)

Registrant's telephone number, including area code: **(301) 795-1800**

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On January 10, 2011, Emergent BioSolutions Inc. announced preliminary unaudited financial results for 2010 and guidance for 2011. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 10, 2011

EMERGENT BIOSOLUTIONS INC.

By: /s/ R. Don Elsey

R. Don Elsey

Chief Financial Officer

Exhibit Index

Exhibit 99.1 - Press release dated January 10, 2011

FOR IMMEDIATE RELEASE

Investors Contact:
 Robert G. Burrows
 Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com

Media Contact:
 Tracey Schmitt
 Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS PROVIDES PRELIMINARY 2010 FINANCIAL RESULTS AND GUIDANCE FOR 2011

- **Anticipated for 2010: Revenue of \$285 to \$288 Million; Net Income of \$48 to \$51 Million; Year End Combined Cash and Accounts Receivable Balance in Excess of \$200 Million**
- **Forecasted for 2011: Total Revenue of \$320 to \$340 Million and Net Income of \$35 to \$45 Million**

ROCKVILLE, MD, January 10, 2011 —Emergent BioSolutions Inc. (NYSE: EBS) announced today preliminary, unaudited financial results for 2010 and guidance for 2011.

For 2010, the Company estimates total revenue of \$285 to \$288 million, split between product sales of approximately \$251 million and contracts and grants of \$34 to \$37 million. The Company also estimates net income of \$48 to \$51 million. The Company ended the year with a combined cash and accounts receivable balance in excess of \$200 million. The Company's accounts receivable balance consists primarily of amounts due related to shipments of BioThrax[®] received and accepted by the US government, but for which payment is forthcoming.

For 2011, the Company is forecasting total revenue of \$320 to \$340 million, an increase of up to 19 percent, split between product sales of \$255 to \$265 million and contracts and grants of \$65 to \$75 million. The Company also is forecasting net income of \$35 to \$45 million.

2011 total revenue is expected to be driven by, among other things:

- the continuation of deliveries of BioThrax[®] under the current multi-year procurement contract with CDC;
- additional deliveries of BioThrax[®] under a follow-on, multi-year procurement contract with CDC, anticipated to be executed during 1Q 2011 and to begin in 4Q 2011;
- a significant increase in contracts and grants revenue based primarily on development contracts already in place that are funding the validation and qualification of BioThrax[®] in the Company's large-scale manufacturing facility and the further development of Previthrax[™] (rPA); and,
- collaboration and milestone revenues associated with achievement of clinical development milestones related to the Company's oncology product candidate, which is under an existing co-development agreement with Abbott, and the Company's autoimmune product candidate, which was out-licensed to Pfizer.

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc., stated, "We are delighted with our 2010 performance and are enthusiastic about the prospects for continued growth in 2011. We look forward to continuing to work with the U.S. government on supplying BioThrax as well as developing additional medical countermeasures in support of their long term commitment to safe guard the American public against biological agents. We are also excited about the prospect of further developing our infectious disease vaccines and oncology and autoimmune disease therapeutics."

The 2010 results will be finalized upon the completion of the Company's external audit, anticipated in early March 2011.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed and investigational products target infectious diseases, oncology, and autoimmune disorders. Additional information about the Company may be found at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our estimates of preliminary results for 2010, and our expected revenue growth and net earnings for 2011, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax[®] procurement; our ability to obtain new BioThrax[®] sales contracts; our plans to pursue label expansions and improvements for BioThrax[®]; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; and other factors identified in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 and subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.



